Abstract 3886: Clec12a: A new AML stem cell-associated antigen

Viviana Guadagnuolo(University of Bologna), Giovanni Martinelli(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Emanuela Ottaviani(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonella Padella(University of Bologna), Enrica Imbrogno(University of Bologna), Simona Soverini(University of Bologna), Ilaria Iacobucci(Istituto Oncologico Romagnolo), Anna Ferrari(University of Bologna)
Cancer Research
October 1, 2014
10.1158/1538-7445.am2014-3886
Cited by 0

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486